Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devonian Health GroupDVHGF 59 Debt-to-EBITDA is -0.02 as of Apr. 2026. GuruFocus rates DVHGF with a GF Score™ of 59/100 and a GF Value™ of $2.01 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 298 Biotechnology companies, Devonian Health Group ranks worse than 335570.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Devonian Health Group's Debt-to-EBITDA or its related term are showing as below:
DVHGF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.07 Med: -1.82 Max: 35.65
Current: -0.02
During the past 12 years, the highest Debt-to-EBITDA Ratio of Devonian Health Group was 35.65. The lowest was -4.07. And the median was -1.82.
DVHGF's Debt-to-EBITDA is ranked worse than 100% of 298
companies
in the Biotechnology industry
Industry Median: 1.23
vs DVHGF: -0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Devonian Health Group Debt-to-EBITDA Related Terms
Devonian Health Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Devonian Health Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
Devonian Health Group (DVHGF) has a Debt-to-EBITDA of -0.02 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Devonian Health Group. According to the industry distribution chart, Devonian Health Group ranks #999999 out of 298 companies in the Biotechnology industry.
Is Devonian Health Group's Debt-to-EBITDA too high?
Devonian Health Group's current Debt-to-EBITDA is -0.02. Based on the distribution chart, Devonian Health Group ranks #999999 out of 298 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #999999 out of 298 companies for Debt-to-EBITDA. This places Devonian Health Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.23, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Devonian Health Group. For the Biotechnology industry, the median Debt-to-EBITDA is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devonian Health Group's current Debt-to-EBITDA is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.01, compared to a current price of $7.00 — trading 248.3% above its estimated fair value. The current Debt-to-EBITDA is -0.02. Devonian Health Group's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Debt-to-EBITDA is -0.02 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 248.3% above its estimated GF Value™ of $2.01.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Debt-to-EBITDA: -0.02
GF Value™: $2.01 vs. price of $7.00 (248.3% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
59GF Score
Get the complete analysis for DVHGF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
